Navigation Links
12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
Date:3/28/2012

SINGAPORE, March 28, 2012 /PRNewswire/ -- Novus Scientific, manufacturer of TIGR® Matrix Surgical Mesh, the world's first long-term resorbable (100% absorbable) synthetic mesh, proudly announces the presentation of 12 month TRAM flap data gathered by the Division of Plastic Reconstructive and Aesthetic Surgery at NUH Singapore.

The pedicled transverse rectus abdominis myocutaneous (TRAM) flap is a workhorse of autologous breast reconstruction. The main drawback most surgeons have with this option is in the donor site morbidity. Very often, the rectus sheath cannot be closed primarily and the defect has to be bridged using a mesh. Even if the rectus sheath can be apposed, the patient is at risk of having an abdominal hernia from weakness of the abdominal wall. The ideal situation, elaborates Dr Ong, would be to use a non-permanent on-lay graft over the primary repair to strengthen the sheath repair. The graft would give additional strength until fibrosis has set in to provide the additional strength to the repair, and then the mesh would resorb, to minimize the problems associated with the use of a permanent mesh.

"We assessed the early results with the use of a synthetic resorbable mesh as an on-lay graft over our rectus sheath repair in patients who had undergone pedicled TRAM flap for breast reconstruction. All patients were randomized into either using this synthetic resorbable mesh (TIGR® Matrix Surgical Mesh) or a synthetic permanent mesh. Data was collected prospectively, as well as on follow up. Our results showed that there was no significant difference in complication rates between the two groups, up to a follow up of 1 year. There was no difference in patient recovery, hospitalization stay, and pain scores," said Dr. Ong Wei Chen, Consultant Plastic Surgeon,  Division of Plastic, Reconstructive and Aesthetic S
'/>"/>

SOURCE Novus Scientific
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. March is Endometriosis Awareness Month
2. HASCO Medical Announces its Fourth Acquisition in the Last 9 Months With the Purchase of Ride-Away
3. NMEDA Introduces National Mobility Awareness Month for Seniors, Veterans and People with Disabilities
4. Drugs & Bugs: A New App from Monthly Prescribing Reference
5. Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Months Supply of New Product Immediately and on Track to Ensure Sustainable Supply
6. Mercy Jets Celebrates Heart Month With Charitable Donations
7. Misonix Reports a 29% and 24% Increase in Revenue for the Second Quarter and Six Months Fiscal 2012 Financial Results
8. 69-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month
9. Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results
10. In Honor of American Heart Month, Joy Behar & Daughter Eve Call on Women to Take the ProHeart Pledge on Facebook
11. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... SGP ), a leader in hepatitis research, ... III studies of boceprevir, its,investigational oral hepatitis C ... virus (HCV) genotype 1. One study,will be in ... patients,who failed prior treatment (relapsers and nonresponders), an ...
... Laboratories, L.C., a,privately-owned biopharmaceutical company, today announced the ... to evaluate the safety and,efficacy of nitazoxanide in ... with chronic hepatitis C genotype 1 who have ... therapy (peginterferon and,ribavirin). The company expects to announce ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... 22, 2014) The International Communication Association will ... Seattle, Washington. The theme of the 2014 conference ... a networked and digital society. , Featuring over ... over 2,200 Communication scholars representing over 40 countries, ... communication conference in the world. This year,s conference ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... tools, but ,talking, computer program helped , , FRIDAY, ... the written questions American doctors have them answer ... question the usefulness of these screening tools, new ... year at the 2008 Clinical Congress of the ...
... WASHINGTON, Oct. 17 After a destructive,hurricane season that ... the American Public Health Association (APHA) wants to ensure,that ... storms and any other,potential emergencies you may face. With ... a new campaign aimed at encouraging Americans to,make sure ...
... AUBURN HILLS, Mich., Oct. 17 Chrysler LLC ... companies will bring an,innovative diabetes program to its ... developed with the Henry Ford Health System,and is ... and,care with existing workplace wellness initiatives. All employees ...
... into tobacco dependence published online today (Friday 17 October 2008) ... that recent ex-smokers who find exposure to other people,s cigarette ... those who find it unpleasant. , Led by Dr Hayden ... Unit at Barts and The London School of Medicine and ...
... ShotsTM Brings Public Health Message to Austin,s American,Heart ... Heart disease was the leading,cause of death ... in every,10 deaths. People with heart disease are ... complications from the flu. Therefore, the,U.S. Centers for ...
... break fundraising records for breast ... cancer research, SEATTLE, ... Breast Cancer Awareness month to raise money for breast,cancer research. This is ... to help breast cancer research and who has,not completed their will to ...
Cached Medicine News:Health News:Doctors Often Overestimate Patients' Health Literacy 2Health News:Check Your Emergency Preparedness Kits When You Set Your Clocks, Says American Public Health Association Campaign 2Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:How Can Doing Your Will Online Help Cure Breast Cancer? 2
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... heart, the only therapy solution open to them is ... are not always readily available. For this reason, too ... list for a donor organ. , ,This is where ... a patient. On the one hand, these systems can ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
... The Nichols Advantage® 25-Hydroxyvitamin D Assay ... Advantage® Specialty System. The Nichols Advantage® 25-Hydroxyvitamin ... determination of 25-,hydroxyvitamin D (25-OH-D) and other ... or plasma to be used as an ...
Medicine Products: